Texas 2013 - 83rd Regular

Texas House Bill HB124 Compare Versions

The same version is selected twice. Please select two different versions to compare.

Version 1 (Old)

Version 2 (New)

Old	New	Differences
1	1	By: Anderson, et al. (Senate Sponsor - Campbell) H.B. No. 124
2	2	(In the Senate - Received from the House May 3, 2013;
3	3	May 6, 2013, read first time and referred to Committee on Criminal
4	4	Justice; May 17, 2013, reported favorably by the following vote:
5	5	Yeas 7, Nays 0; May 17, 2013, sent to printer.)
6	6
7	7
8	8	A BILL TO BE ENTITLED
9	9	AN ACT
10	10	relating to the addition of Salvia divinorum and its derivatives
11	11	and extracts to Penalty Group 3 of the Texas Controlled Substances
12	12	Act.
13	13	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
14	14	SECTION 1. Section 481.104(a), Health and Safety Code, is
15	15	amended to read as follows:
16	16	(a) Penalty Group 3 consists of:
17	17	(1) a material, compound, mixture, or preparation that
18	18	contains any quantity of the following substances having a
19	19	potential for abuse associated with a stimulant effect on the
20	20	central nervous system:
21	21	Methylphenidate and its salts; and
22	22	Phenmetrazine and its salts;
23	23	(2) a material, compound, mixture, or preparation that
24	24	contains any quantity of the following substances having a
25	25	potential for abuse associated with a depressant effect on the
26	26	central nervous system:
27	27	a substance that contains any quantity of a
28	28	derivative of barbituric acid, or any salt of a derivative of
29	29	barbituric acid not otherwise described by this subsection;
30	30	a compound, mixture, or preparation containing
31	31	amobarbital, secobarbital, pentobarbital, or any salt of any of
32	32	these, and one or more active medicinal ingredients that are not
33	33	listed in any penalty group;
34	34	a suppository dosage form containing amobarbital,
35	35	secobarbital, pentobarbital, or any salt of any of these drugs, and
36	36	approved by the United States Food and Drug Administration for
37	37	marketing only as a suppository;
38	38	Alprazolam;
39	39	Amobarbital;
40	40	Bromazepam;
41	41	Camazepam;
42	42	Chlordiazepoxide;
43	43	Chlorhexadol;
44	44	Clobazam;
45	45	Clonazepam;
46	46	Clorazepate;
47	47	Clotiazepam;
48	48	Cloxazolam;
49	49	Delorazepam;
50	50	Diazepam;
51	51	Estazolam;
52	52	Ethyl loflazepate;
53	53	Fludiazepam;
54	54	Flurazepam;
55	55	Glutethimide;
56	56	Halazepam;
57	57	Haloxzolam;
58	58	Ketazolam;
59	59	Loprazolam;
60	60	Lorazepam;
61	61	Lormetazepam;
62	62	Lysergic acid, including its salts, isomers, and
63	63	salts of isomers;
64	64	Lysergic acid amide, including its salts,
65	65	isomers, and salts of isomers;
66	66	Mebutamate;
67	67	Medazepam;
68	68	Methyprylon;
69	69	Midazolam;
70	70	Nimetazepam;
71	71	Nitrazepam;
72	72	Nordiazepam;
73	73	Oxazepam;
74	74	Oxazolam;
75	75	Pentazocine, its salts, derivatives, or compounds
76	76	or mixtures thereof;
77	77	Pentobarbital;
78	78	Pinazepam;
79	79	Prazepam;
80	80	Quazepam;
81	81	Secobarbital;
82	82	Sulfondiethylmethane;
83	83	Sulfonethylmethane;
84	84	Sulfonmethane;
85	85	Temazepam;
86	86	Tetrazepam;
87	87	Tiletamine and zolazepam in combination, and its
88	88	salts. (some trade or other names for a tiletamine-zolazepam
89	89	combination product: Telazol, for tiletamine: 2-(ethylamino)-
90	90	2-(2-thienyl)-cyclohexanone, and for zolazepam: 4-(2-
91	91	fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-
92	92	e](1,4)-d diazepin-7(1H)-one, flupyrazapon);
93	93	Triazolam;
94	94	Zaleplon;
95	95	Zolpidem; and
96	96	Zopiclone;
97	97	(3) Nalorphine;
98	98	(4) a material, compound, mixture, or preparation
99	99	containing limited quantities of the following narcotic drugs, or
100	100	any of their salts:
101	101	not more than 1.8 grams of codeine, or any of its
102	102	salts, per 100 milliliters or not more than 90 milligrams per dosage
103	103	unit, with an equal or greater quantity of an isoquinoline alkaloid
104	104	of opium;
105	105	not more than 1.8 grams of codeine, or any of its
106	106	salts, per 100 milliliters or not more than 90 milligrams per dosage
107	107	unit, with one or more active, nonnarcotic ingredients in
108	108	recognized therapeutic amounts;
109	109	not more than 300 milligrams of dihydrocodeinone
110	110	(hydrocodone), or any of its salts, per 100 milliliters or not more
111	111	than 15 milligrams per dosage unit, with a fourfold or greater
112	112	quantity of an isoquinoline alkaloid of opium;
113	113	not more than 300 milligrams of dihydrocodeinone
114	114	(hydrocodone), or any of its salts, per 100 milliliters or not more
115	115	than 15 milligrams per dosage unit, with one or more active,
116	116	nonnarcotic ingredients in recognized therapeutic amounts;
117	117	not more than 1.8 grams of dihydrocodeine, or any
118	118	of its salts, per 100 milliliters or not more than 90 milligrams per
119	119	dosage unit, with one or more active, nonnarcotic ingredients in
120	120	recognized therapeutic amounts;
121	121	not more than 300 milligrams of ethylmorphine, or
122	122	any of its salts, per 100 milliliters or not more than 15 milligrams
123	123	per dosage unit, with one or more active, nonnarcotic ingredients
124	124	in recognized therapeutic amounts;
125	125	not more than 500 milligrams of opium per 100
126	126	milliliters or per 100 grams, or not more than 25 milligrams per
127	127	dosage unit, with one or more active, nonnarcotic ingredients in
128	128	recognized therapeutic amounts;
129	129	not more than 50 milligrams of morphine, or any of
130	130	its salts, per 100 milliliters or per 100 grams with one or more
131	131	active, nonnarcotic ingredients in recognized therapeutic amounts;
132	132	and
133	133	not more than 1 milligram of difenoxin and not
134	134	less than 25 micrograms of atropine sulfate per dosage unit;
135	135	(5) a material, compound, mixture, or preparation that
136	136	contains any quantity of the following substances:
137	137	Barbital;
138	138	Chloral betaine;
139	139	Chloral hydrate;
140	140	Ethchlorvynol;
141	141	Ethinamate;
142	142	Meprobamate;
143	143	Methohexital;
144	144	Methylphenobarbital (Mephobarbital);
145	145	Paraldehyde;
146	146	Petrichloral; and
147	147	Phenobarbital;
148	148	(6) Peyote, unless unharvested and growing in its
149	149	natural state, meaning all parts of the plant classified
150	150	botanically as Lophophora, whether growing or not, the seeds of the
151	151	plant, an extract from a part of the plant, and every compound,
152	152	manufacture, salt, derivative, mixture, or preparation of the
153	153	plant, its seeds, or extracts;
154	154	(7) unless listed in another penalty group, a
155	155	material, compound, mixture, or preparation that contains any
156	156	quantity of the following substances having a stimulant effect on
157	157	the central nervous system, including the substance's salts,
158	158	optical, position, or geometric isomers, and salts of the
159	159	substance's isomers, if the existence of the salts, isomers, and
160	160	salts of isomers is possible within the specific chemical
161	161	designation:
162	162	Benzphetamine;
163	163	Cathine [(+)-norpseudoephedrine];
164	164	Chlorphentermine;
165	165	Clortermine;
166	166	Diethylpropion;
167	167	Fencamfamin;
168	168	Fenfluramine;
169	169	Fenproporex;
170	170	Mazindol;
171	171	Mefenorex;
172	172	Modafinil;
173	173	Pemoline (including organometallic complexes and
174	174	their chelates);
175	175	Phendimetrazine;
176	176	Phentermine;
177	177	Pipradrol;
178	178	Sibutramine; and
179	179	SPA [(-)-1-dimethylamino-1,2-diphenylethane];
180	180	(8) unless specifically excepted or unless listed in
181	181	another penalty group, a material, compound, mixture, or
182	182	preparation that contains any quantity of the following substance,
183	183	including its salts:
184	184	Dextropropoxyphene (Alpha-(+)-4-dimethylamino-
185	185	1,2-diphenyl-3-methyl-2-propionoxybutane); [and]
186	186	(9) an anabolic steroid, including any drug or
187	187	hormonal substance, or any substance that is chemically or
188	188	pharmacologically related to testosterone, other than an estrogen,
189	189	progestin, dehydroepiandrosterone, or corticosteroid, and promotes
190	190	muscle growth, including the following drugs and substances and any
191	191	salt, ester, or ether of the following drugs and substances:
192	192	Androstanediol;
193	193	Androstanedione;
194	194	Androstenediol;
195	195	Androstenedione;
196	196	Bolasterone;
197	197	Boldenone;
198	198	Calusterone;
199	199	Clostebol;
200	200	Dehydrochlormethyltestosterone;
201	201	Delta-1-dihydrotestosterone;
202	202	Dihydrotestosterone (4-dihydrotestosterone);
203	203	Drostanolone;
204	204	Ethylestrenol;
205	205	Fluoxymesterone;
206	206	Formebulone;
207	207	Furazabol;
208	208	13beta-ethyl-17beta-hydroxygon-4-en-3-one;
209	209	4-hydroxytestosterone;
210	210	4-hydroxy-19-nortestosterone;
211	211	Mestanolone;
212	212	Mesterolone;
213	213	Methandienone;
214	214	Methandriol;
215	215	Methenolone;
216	216	17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha-
217	217	androstane;
218	218	17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha-
219	219	androstane;
220	220	17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-
221	221	ene;
222	222	17alpha-methyl-4-hydroxynandrolone;
223	223	Methyldienolone;
224	224	Methyltestosterone;
225	225	Methyltrienolone;
226	226	17alpha-methyl-delta-1-dihydrotestosterone;
227	227	Mibolerone;
228	228	Nandrolone;
229	229	Norandrostenediol;
230	230	Norandrostenedione;
231	231	Norbolethone;
232	232	Norclostebol;
233	233	Norethandrolone;
234	234	Normethandrolone;
235	235	Oxandrolone;
236	236	Oxymesterone;
237	237	Oxymetholone;
238	238	Stanozolol;
239	239	Stenbolone;
240	240	Testolactone;
241	241	Testosterone;
242	242	Tetrahydrogestrinone; and
243	243	Trenbolone; and
244	244	(10) Salvia divinorum, unless unharvested and growing
245	245	in its natural state, meaning all parts of that plant, whether
246	246	growing or not, the seeds of that plant, an extract from a part of
247	247	that plant, and every compound, manufacture, salt, derivative,
248	248	mixture, or preparation of that plant, its seeds, or extracts,
249	249	including Salvinorin A.
250	250	SECTION 2. This Act takes effect September 1, 2013.
251	251	* * * * *